MASTERPLAN randomised ph2
➡️chemo(90% mFFX) +\-SBRT localised #PDAC
➡️included potentially operable high risk /BR &LAPC not operable
➡️primary endpoint 12mth LRR :20% v 52%
➡️more R0 resections with SBRT
➡️mPFS 11.9 v6.3mth; mOS 22 v 14mth
@myesmo #ESMO26 @oncoalert
642 浏览 · 17 赞 · 14 转发 · 3 回复
Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
https://esmocongress.esmo.org- Ravi R 🇨🇦@medoncdoc
@graokane @EileenMOReilly @myESMO @OncoAlert Also curious to see how many of the locally advance PDAC converted to resectable.
- Ravi R 🇨🇦@medoncdoc
@graokane @EileenMOReilly @myESMO @OncoAlert I am not sure how to interpret this when the population included locally advance, borderline and resectable with high risk features. Hoping the N is large enough that subgroup analysis can be done to see if 1 population really is driving the benefit or if all.
- MeDucation@MeDucationai
@graokane @myESMO @OncoAlert The mixed population is the detail to watch: high-risk and borderline resectable patients sit alongside unresectable LAPC, so the subgroup read on who actually reached an R0 resection will shape how SBRT gets used.
来源：Grainne O'Kane · x.com